According to the business intelligence report titled ‘Global bovine mastitis market size study by Type (Clinical and Sub-Clinical), Product (Antibiotics, Surgery, Vaccines, Pain Killers, and Others), Route of Administration (Intra-Mammary and Systemic), By Therapy (Lactating Period and Dry Period), End Users (Hospitals, Veterinary Centers, and Others), Regional Forecasts 2021-2027’, available with MarketStudyReport, global bovine mastitis market is expected to exceed a CAGR of 5.1% over 2021-2027.
 

As per the findings of the report, global bovine mastitis market is mainly driven by rising prevalence of the disease, as well as increase in launches of animal healthcare products.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4219637/
 

For the uninitiated, bovine mastitis is an ailment that affects dairy animals, causing inflammation in the mammary gland and udder tissue. It is a major problem as it affects the milk-secreting tissues of the cattle. Besides, the disease is also considered a hazard to human health as it can cause zoonoses and food toxin infections.
 

Expert analysts cite that lack of awareness regarding the disease may hinder industry growth during the analysis timeframe.
 

From a regional frame of reference, as per the report, global bovine mastitis market is spread across North America, Europe, Asia Pacific, and Latin America. The research report provides a comprehensive analysis of both qualitative as well as quantitative aspects of the market within all of these regions.
 

It has been observed that North America is the most promising region in this business sphere, mainly due to the establishment of reputed companies in the region, as well as the high preference towards intra-mammary infusion products for treatment of bovine mastitis.
 

Speaking of the competitive landscape, DeLaval, Westway Health, Merck & Co., Ltd., Zoetis Inc., Nimrod Veterinary Products Ltd, ImmuCell Corporation, Boehringer Ingelheim International GmBH, Norbrook Laboratories, Bayer AG, and Advanced Animal Diagnostics are the major players influencing global bovine mastitis industry trends.
 

The aforementioned companies are making continuous efforts towards R&D to meet the growing expectations of consumers worldwide and amplify their revenues. Boehringer Ingelheim for instance announced the launch of a new medicine in 2018 to prevent dairy cattle from being affected by immunological diseases, called 'Lockout'. It aims to help dairy cattle avoid post-immunotherapy problems and boost their health and performance, thereby enhancing the final products from dairy farming.